Compare Enveric Biosciences Inc (ENVB) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs CarMax, Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while CarMax, Inc trades at $53.88 (market cap $7.56B). The key difference: CarMax, Inc is far larger — about 1130× Enveric Biosciences Inc's market cap, and CarMax, Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and CarMax, Inc for 49 Days on average.
| ENVB | KMX | |
|---|---|---|
Market Cap | $6.69M | $7.56B |
Volume | 41,141 | 3,338,522 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $64.22 |
52-Week Low | $1.27 | $30.88 |
Typical Hold Time | 14 Days | 49 Days |
Enterprise Value | -$1.60M | $25.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
CarMax (KMX) trades at $53.79, down 2.71% with bearish technical signals despite recent earnings beats. The company reported strong Q2 2026 results with EPS of $1.16 beating estimates by 58%, driven by 19.5% revenue growth to $7.9 billion. However, net income margin remains thin at 1.06% and the stock faces resistance near $54 with negative cash flow trends. Management's 'Shift into GEAR' strategy shows early traction with improved unit sales and pricing power.
KMX presents a mixed outlook with valuation support (P/S 0.28) offset by margin pressure and high debt load. Analyst consensus targets $58.89 (9.5% upside) but technical weakness suggests near-term consolidation. Key risks include used car market volatility and interest rate sensitivity given $18.1B long-term debt. The turnaround story requires sustained execution to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
